Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$54.66

0.74 (1.37%)

17:19
10/03/16
10/03
17:19
10/03/16
17:19

Bristol-Myers Squibb to present Opdivo, Yervoy data at ESMO congress

Bristol-Myers Squibb announced new data across eight tumor types evaluating Opdivo and Yervoy as monotherapy or in combination, as well as new assets, to be presented at the 2016 European Society for Medical Oncology Congress in Copenhagen, Denmark from October 7-11. Data presented at this congress underscore the company's commitment to its portfolio and to discover the next wave of transformational Immuno-Oncology medicines, including combination therapies, for difficult-to-treat cancers. "Bristol-Myers Squibb continues to lead the scientific understanding of Immuno-Oncology with an extensive portfolio and a differentiated clinical development program where we have set a high bar of success to look for clear and differentiated improvements over currently available therapies," said Fouad Namouni, M.D., head of development, Oncology, Bristol-Myers Squibb. "We remain focused on expanding the use of the Opdivo and Yervoy combination to more tumors, and bringing forward novel agents and combination regimens in earlier lines of therapy, to help even more patients with cancer."

  • 09

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$54.66

0.74 (1.37%)

09/12/16
JEFF
09/12/16
NO CHANGE
Target $57
JEFF
Hold
Jefferies cuts Bristol-Myers price target, upgrades AstraZeneca
Jefferies analyst Jeffrey Holford lowered his price target for Bristol-Myers Squibb (BMY) to $57 from $69 saying the stock is positioned for a "rough mid term ride." The analyst sees a "difficult catalyst" set for Bristol shares with "numerous" upcoming competitor read-outs in non-small cell lung cancer. The market could see worse than expected data from Bristol's CM-026 and CM-568 studies as well as better than expected data from AstraZeneca's (AZN) MYSTIC study and Roche's (RHHBY) Chemo-IO studies in the first half of 2017, Holford tells investors in a research note. He keeps a Hold rating on Bristol and upgraded this morning AstraZeneca to Buy from Hold. Holford prefers Astra for its immunology exposure.
09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

NXTM

NxStage Medical

$23.46

0.13 (0.56%)

21:43
06/26/17
06/26
21:43
06/26/17
21:43
Initiation
NxStage Medical initiated  »

NxStage Medical initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

21:40
06/26/17
06/26
21:40
06/26/17
21:40
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

BL

BlackLine

$37.80

-0.26 (-0.68%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
BlackLine initiated  »

BlackLine initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ULTI

Ultimate Software

$221.91

-0.25 (-0.11%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Ultimate Software initiated  »

Ultimate Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CRM

Salesforce

$88.11

-0.51 (-0.58%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Salesforce initiated  »

Salesforce initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVBG

Everbridge

$24.66

-0.3 (-1.20%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Everbridge initiated  »

Everbridge initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNG

RingCentral

$37.65

-1 (-2.59%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
RingCentral initiated  »

RingCentral initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WK

Workiva

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
Workiva initiated  »

Workiva initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:56
06/26/17
06/26
20:56
06/26/17
20:56
Initiation
HubSpot initiated  »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

HUBS

HubSpot

$68.20

-0.7 (-1.02%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
HubSpot initiated  »

HubSpot initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

QTWO

Q2 Holdings

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Q2 Holdings initiated  »

Q2 Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

  • 28

    Jun

  • 29

    Jun

INST

Instructure

$29.55

0.4 (1.37%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Instructure initiated  »

Instructure initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

MANH

Manhattan Associates

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Manhattan Associates initiated  »

Manhattan Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCTY

Paylocity

$47.39

-1.65 (-3.36%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Paylocity initiated  »

Paylocity initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

SHOP

Shopify

$92.04

-2.44 (-2.58%)

20:55
06/26/17
06/26
20:55
06/26/17
20:55
Initiation
Shopify initiated  »

Shopify initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LH

LabCorp

$152.30

0.68 (0.45%)

20:10
06/26/17
06/26
20:10
06/26/17
20:10
Downgrade
LabCorp rating change  »

LabCorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATXI

Avenue Therapeutics

20:06
06/26/17
06/26
20:06
06/26/17
20:06
Syndicate
Avenue Therapeutics 5.5M share IPO priced at $6.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

NXPI

NXP Semiconductors

$109.73

-0.25 (-0.23%)

20:05
06/26/17
06/26
20:05
06/26/17
20:05
Hot Stocks
NXP Semi collaborates with Shanghai Unicom, roam2free on eSIM solution »

NXP Semiconductors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 26

    Jun

PDCE

PDC Energy

$42.88

-1.84 (-4.11%)

19:21
06/26/17
06/26
19:21
06/26/17
19:21
Hot Stocks
PDC Energy CEO 'disappointed' with Clean Air Act complaint »

Today, the U.S.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

MRIN

Marin Software

$1.18

0.025 (2.17%)

19:17
06/26/17
06/26
19:17
06/26/17
19:17
Hot Stocks
Marin Software names Brad Kinnish CFO »

Marin Software announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

19:15
06/26/17
06/26
19:15
06/26/17
19:15
Earnings
General Motors: Previous FY17 EPS view unchanged »

General Motors said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

GM

General Motors

$34.52

0.32 (0.94%)

19:04
06/26/17
06/26
19:04
06/26/17
19:04
Hot Stocks
General Motors lowers view of 2017 U.S. car industry »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

, CST

CST Brands

$48.54

0.18 (0.37%)

18:56
06/26/17
06/26
18:56
06/26/17
18:56
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P SmallCap 600…

BLKB

Blackbaud

$89.25

-0.25 (-0.28%)

CST

CST Brands

$48.54

0.18 (0.37%)

NSA

National Storage

$22.63

0.22 (0.98%)

ANCUF

Alimentation Couche-Tard

$48.08

1.9887 (4.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$34.52

0.32 (0.94%)

18:52
06/26/17
06/26
18:52
06/26/17
18:52
Hot Stocks
General Motors raises expected Opel sale charge to $5.5B »

On a conference call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 25

    Jul

WMT

Wal-Mart

$75.50

0.66 (0.88%)

18:43
06/26/17
06/26
18:43
06/26/17
18:43
Periodicals
Wal-Mart sued for wrongful death of Illinois Uber driver, Reuters reports »

The family of an Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.